Group structure
10 companies in 4 countries
Loading your pageโฆ
Loading your pageโฆ
10 companies in 4 countries
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine of every company in the group, current ones first.
1โ25 of 29
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Crysvita20mg/ml ยท Injection | Burosumab | United States | Marketed | 2018 |
| CRYSVITA30 mg / ml ยท Solution | Burosumab | Canada | Marketed | 2019 |
| CRYSVITA10mg/ml ยท Injectable | Burosumab | United States | Marketed | 2018 |
| CRYSVITASoluzione iniettabile | Burosumab | Italy | Authorised | |
| CRYSVITA20 mg / ml ยท Solution | Burosumab | Canada | Marketed | 2019 |
| CRYSVITA10 mg / ml ยท Solution | Burosumab | Canada | Marketed | 2019 |
| Crysvita30mg/ml ยท Injection | Burosumab | United States | Marketed | 2018 |
| Crysvita | Burosumab | EU (EMA) | Authorised | 2018 |
| CRYSVITA 10 mg oplossing voor injectieOplossing voor injectie | Burosumab | Netherlands | Authorised | 2018 |
| CRYSVITA 10 MG SOLUCION INYECTABLE10 mg ยท Soluciรณn inyectable | Burosumab | Spain | Marketed | 2018 |
| CRYSVITA 10 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA10 mg ยท Solucion para perfusion en jeringa precargada | Burosumab | Spain | Marketed | 2024 |
| CRYSVITA 20 mg oplossing voor injectieOplossing voor injectie | Burosumab | Netherlands | Authorised | 2018 |
| CRYSVITA 20 MG SOLUCION INYECTABLE20 mg ยท Soluciรณn inyectable | Burosumab | Spain | Marketed | 2018 |
| CRYSVITA 20 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA20 mg ยท Solucion para perfusion en jeringa precargada | Burosumab | Spain | Marketed | 2024 |
| CRYSVITA 30 mg oplossing voor injectieOplossing voor injectie | Burosumab | Netherlands | Authorised | 2018 |
| CRYSVITA 30 MG SOLUCION INYECTABLE30 mg ยท Soluciรณn inyectable | Burosumab | Spain | Marketed | 2018 |
| CRYSVITA 30 MG SOLUCION INYECTABLE EN JERINGA PRECARGADA30 mg ยท Solucion para perfusion en jeringa precargada | Burosumab | Spain | Marketed | 2024 |
| FARESTON60mg base ยท Tablet | Toremifene | United States | Not marketed | 1997 |
| NOURIANZ20mg | 40mg ยท Tablet | Istradefylline | United States | Marketed | 2019 |
| Poteligeo | Mogamulizumab | EU (EMA) | Authorised | 2018 |
| POTELIGEOConcentrato per soluzione per infusione | Mogamulizumab | Italy | Authorised | |
| POTELIGEO4 mg / ml ยท Solution | Mogamulizumab | Canada | Marketed | 2024 |
| POTELIGEO20mg/5ml ยท Injectable | Mogamulizumab | United States | Marketed | 2018 |
| POTELIGEO 4 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION20 mg ยท Concentrado para soluciรณn para perfusiรณn | Mogamulizumab | Spain | Marketed | 2019 |
| Poteligeo 4 mg/mL concentratie voor oplossing voor infusieConcentraat voor oplossing voor infusie | Mogamulizumab | Netherlands | Authorised | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Spain | 7 | 7 | 0 | CompaniesAll medicines |
| United States | 6 | 6 | 0 | CompaniesAll medicines |
| Canada | 4 | 4 | 0 | CompaniesAll medicines |
| Netherlands | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 3 | 2 | 1 | CompaniesAll medicines |
| Romania | 3 | 0 | 3 | CompaniesAll medicines |
| Italy | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil, France, Serbia, Singapore, United Kingdom
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Companies are grouped by Prognia from the names regulators publish; not an official corporate structure.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la informaciรณn: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la informaciรณn: Agencia Espaรฑola de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK; Category 1 list; publication updated 25 August 2026; acquired 2026-10-15T08:18:47.757811+00:00; original workbook cells and factual authorization/holder projections adapted under Open Government Licence v3.0.
Licence: Open Government Licence v3.0; exact Crown copyright 2026 publication grant
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/847386/OFFICINE_API_GIUGNO_2025.csv; HTTP Last-Modified Tue, 08 Jul 2025 11:28:20 GMT; acquired 2026-10-13T17:21:05.497592+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://www.aifa.gov.it/documents/20142/3815901/Classe_H_per_principio_attivo_31-05-2026.csv; HTTP Last-Modified Mon, 28 Sep 2026 08:46:40 GMT; acquired 2026-10-13T17:21:06.034935+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
Ministerul Sฤnฤtฤศii, Catalogul public naลฃional al preลฃurilor, 18 iunie 2021, downloaded 2026-10-08 from data.gov.ro; CC BY 4.0; structured factual adaptation, code whitespace trimmed only where explicitly recorded.
Licence: Creative Commons Attribution 4.0 International (CC BY 4.0)
ALIMS, Registar humanih lekova, source 08.10.2026 02:00, downloaded 2026-10-08, https://data.gov.rs/sr/datasets/lekovi-za-upotrebu-u-khumanoj-meditsini/; structured factual adaptation; Serbian Open Data Licence.
Licence: Serbian Open Data Licence (sodl)
Contains information from HSA Listing of Registered Therapeutic Products accessed on 8 October 2026 from data.gov.sg, under Singapore Open Data Licence 1.0: https://data.gov.sg/open-data-licence
Licence: Singapore Open Data Licence
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Well-known pharmaceutical groups, each with all its companies.